Henry Schein, Inc. $HSIC Stock Holdings Lessened by Marathon Asset Management Ltd

Marathon Asset Management Ltd lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 26.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 171,888 shares of the company’s stock after selling 61,529 shares during the period. Marathon Asset Management Ltd’s holdings in Henry Schein were worth $11,408,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the second quarter valued at $25,000. MUFG Securities EMEA plc purchased a new stake in shares of Henry Schein during the 2nd quarter worth about $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Henry Schein during the 2nd quarter valued at about $43,000. Steph & Co. acquired a new stake in shares of Henry Schein during the 2nd quarter valued at about $44,000. Finally, CX Institutional grew its stake in shares of Henry Schein by 107.3% in the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock valued at $48,000 after buying an additional 337 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $76.13 on Monday. The firm has a market capitalization of $8.96 billion, a PE ratio of 24.09, a price-to-earnings-growth ratio of 2.33 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.49. The firm has a 50-day moving average price of $71.79 and a 200 day moving average price of $69.96.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The firm had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Research analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HSIC has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Morgan Stanley lifted their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Barclays began coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Wells Fargo & Company raised their target price on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Finally, Barrington Research set a $79.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and an average target price of $76.92.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.